Skip to main content
. 2022 Jun 21;18:100154. doi: 10.1016/j.ahjo.2022.100154

Table 2.

SGLT2-inhibitor use.

SGTL2-inhibitor initiation
Time from LVAD implantation to SGLT2-inhibitor initiation (n = 34) 659.3 ± 703
SGTL2-inhibitor
 Canagliflozin 2 (5.9 %)
 Empagliflozin 22 (64.7 %)
 Dapagliflozin 10 (29.4 %)
 Ertugliflozin 0 (0 %)
Timing of SGLT2-I initiation
 Prior to VAD implant 2 (5.9 %)
 During VAD implant admission 0 (0 %)
 Post VAD implant admission 32 (94.1 %)